omega 3's- research pubMed-neuropathy-3 of many

[Guest guest]

1: J Diabetes Complications. 1996 Sep-Oct;10(5):280-7.

Related Articles, Links

? 

Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and

serum

lipids in patients with type II diabetes mellitus.

Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, Isaka M, Suzuki S,

Kawakami

Y, Field JB, Yamashita K.

Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan.

The present study was undertaken to investigate the efficacy of a new, highly

purified

(purity greater than 91%), ethyl esterification product from natural

eicosapentaenoic acid

(EPA-E, C20:5 omega 3) in patients with type II diabetes mellitus (NIDDM).

Hemodynamic

changes were assessed at the level of the dorsalis pedis artery using an

ultrasonic color

Doppler duplex system before and after oral administration of EPA-E at a dose of

1800

mg/day for 48 weeks. The cross-sectional area of the dorsalis pedis artery

increased

significantly from 2.5 +/- 0.2 to 3.9 +/- 0.4 mm2 (48 weeks, mean +/- SE, p <

0.05).

Moreover, EPA-E improved the clinical symptom (coldness, numbness) as well as

the

vibration perception threshold sense of the lower extremities [from 32.1 +/- 8.5

to 16.1

+/- 4.8 (48 weeks) microns]. A significant decrease of serum triglycerides was

also noted

by EPA-E administration. Furthermore, significant decrease of the excretion of

albumin in

urine [from 24.4 +/- 3.3 to 13.9 +/- 1.8 (48 weeks) mg/g.Cr, p < 0.05]. The

results of

this study suggest that EPA-E has significant beneficial effects on diabetic

neuropathy and

serum lipids as well as other diabetic complications such as nephropathy and

macroangiopathy.

PMID: 8887017 [PubMed - indexed for MEDLINE]

********************

1: Acta Ophthalmol Scand Suppl. 1998;(227):41-2.

Related Articles, Links

Fatty acid use in glaucomatous optic neuropathy treatment.

Cellini M, Caramazza N, Mangiafico P, Possati GL, Caramazza R.

Oculistics Clinic, University of Bologna.

The authors have studied the efficacy of an association of DHA, vitamin E and

vitamin B

complex (TROFINERV) in glaucomatous patients. The parameters evaluated were

computerized visual field (CVF) and retinal contrast sensitivity (RCS). Thirty

chronic simple

glaucoma patients in good tensional compensation with local therapy were given

TROFINERV oral therapy. The results show significant differences after 90 days

of

treatment both in the perimetric indices (MD, SF, CPSD; p < 0.05) and in the RCS

frequency

values (p < 0.05). In the light of the results obtained, the authors consider

the use of such

association to be a useful support in glaucomatous patient therapy for

preventing or

delaying the progress of damage.

PMID: 9972342 [PubMed - indexed for MEDLINE]

**************************************

1: Diabetes. 2003 Oct;52(10):2578-85.

Related Articles, Links

? 

Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in

experimental

diabetic neuropathy.

Coste TC, Gerbi A, Vague P, Pieroni G, Raccah D.

UPRES EA 2193, Faculte de Medecine Timone, Marseille, France.

Thierry.Coste@...

A deficiency in essential fatty acid metabolism has been widely reported in both

human

and animal diabetes. Fish oil supplementations (n-3 fatty acids), containing

docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), were less effective

on

diabetic neuropathy than (n-6) fatty acids. This partial effect of (n-3) fatty

acids might be

attributed to the presence of EPA, a competitor of arachidonic acid, which

enhanced the

diabetes-induced decrease of this fatty acid in serum and tissues. For

determining

whether a supplementation with DHA alone could prevent neuropathy in

streptozotocin-

induced diabetes, diabetic rats were given daily, by gavage, liposomes

containing DHA

phospholipids, at a dose of 60 mg/kg. Eight weeks of diabetes induced

significant

decreases in nerve conduction velocity (NCV), nerve blood flow (NBF), and

sciatic nerve and

erythrocyte (red blood cells [RBCs]) Na,K-ATPase activities. DHA phospholipids

totally

prevented the decrease in NCV and NBF observed during diabetes when compared

with the

nonsupplemented diabetic group. DHA phospholipids also prevented the Na,K-ATPase

activity decrease in RBC but not in sciatic nerve. Moreover, DHA level in

sciatic nerve

membranes was correlated with NCV. These results demonstrate a protective effect

of

daily doses of DHA on experimental diabetic neuropathy. Thus, treatment with DHA

phospholipids could be suitable for evaluation in clinical trials.

PMID: 14514643 [PubMed - indexed for MEDLINE]

********